Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.57 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | CYBB | P04839 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12138655 | 0.93 | HSD17B2 (0.60) | HSD17B2KDM4EPOLBHDAC6MEN1 | |
| SCHEMBL8886989 | 0.87 | HSD17B2 (0.67) | HSD17B2KDM4EPOLBHDAC6MEN1 | |
| SCHEMBL1356478 | 0.85 | HSD17B2 (0.72) | HSD17B2KDM4EPOLBHDAC6MEN1 | |
| SCHEMBL1354883 | 0.84 | HSD17B2 (0.67) | HSD17B2KDM4EPOLBHDAC6MEN1 | |
| SCHEMBL4955356 | 0.84 | HSD17B2 (0.70) | HSD17B2KDM4EPOLBHDAC6MEN1 | |
| SCHEMBL1356516 | 0.83 | KDM4E (0.85) | HSD17B2KDM4EPOLBHDAC6MEN1 | |
| SCHEMBL12137171 | 0.83 | HSD17B2 (0.79) | HSD17B2KDM4EPOLBHDAC6MEN1 | |
| SCHEMBL1355522 | 0.82 | HSD17B2 (0.50) | HSD17B2KDM4EPOLBHDAC6MEN1 | |
| SCHEMBL155638 | 0.81 | HSD17B2 (1.00) | HSD17B2KDM4EPOLBHDAC6MEN1 | |
| SCHEMBL1355524 | 0.81 | HSD17B2 (0.52) | HSD17B2KDM4EPOLBHDAC6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110280940-A1 | Di-Vanilloyl And Tri-Vanilloyl Derivatives For Use In Anti-Cancer Therapy | KISS ROBERT (BE) | 2011-11-17 | — | — | US | claimed |
| EP-2367545-A1 | DI-VANILLOYL AND TRI-VANILLOYL DERIVATIVES FOR USE IN ANTI-CANCER THERAPY | Université Libre de Bruxelles (BE) | 2011-09-28 | — | — | EP | claimed |
| WO-2010043631-A1 | DI-VANILLOYL AND TRI-VANILLOYL DERIVATIVES FOR USE IN ANTI-CANCER THERAPY | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2010-04-22 | — | — | WO | claimed |
| US-20110280940-A1 | Di-Vanilloyl And Tri-Vanilloyl Derivatives For Use In Anti-Cancer Therapy | KISS ROBERT (BE) | 2011-11-17 | — | — | US | disclosed |
| US-20110280940-A1 | Di-Vanilloyl And Tri-Vanilloyl Derivatives For Use In Anti-Cancer Therapy | KISS ROBERT (BE) | 2011-11-17 | — | — | US | disclosed |
| US-20110280940-A1 | Di-Vanilloyl And Tri-Vanilloyl Derivatives For Use In Anti-Cancer Therapy | KISS ROBERT (BE) | 2011-11-17 | — | — | US | disclosed |
| EP-2367545-A1 | DI-VANILLOYL AND TRI-VANILLOYL DERIVATIVES FOR USE IN ANTI-CANCER THERAPY | Université Libre de Bruxelles (BE) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010043631-A1 | DI-VANILLOYL AND TRI-VANILLOYL DERIVATIVES FOR USE IN ANTI-CANCER THERAPY | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010043631-A1 | DI-VANILLOYL AND TRI-VANILLOYL DERIVATIVES FOR USE IN ANTI-CANCER THERAPY | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110280940-A1 | Di-Vanilloyl And Tri-Vanilloyl Derivatives For Use In Anti-Cancer Therapy | PSEN2, PSEN1, VHL | HSD17B2 1434/4885KDM4E 1847/4885POLB 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.